Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study.
Clin Drug Investig
; 39(6): 553-563, 2019 Jun.
Article
in En
| MEDLINE
| ID: mdl-31037611
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Propionates
/
Carbazoles
/
Peroxisome Proliferator-Activated Receptors
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Clin Drug Investig
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2019
Type:
Article